Nasrin Saki; Fatemeh Sari Aslani; Mohammad Javad Najafzadeh; Roya Radanfar; Seyed Ali Hosseini; Najmeh Ahramiyanpour
Zahra Akbari; Mohammad Shafie'ei; Nastaran Sarvipour; Mohadese Ahmadzade; Hamidreza Rouientan; Saeedeh Farajzadeh; Najmeh Ahramiyanpour
Abstract
Background: Among many coronavirus disease 2019 (COVID-19)integumentary system involvements, alopecia is one of the leastinvestigated. This disorder has been reported in many individualswho have suffered from varying severities of COVID-19. Weaimed to systematically review studies evaluating the onset ...
Read More
Background: Among many coronavirus disease 2019 (COVID-19)integumentary system involvements, alopecia is one of the leastinvestigated. This disorder has been reported in many individualswho have suffered from varying severities of COVID-19. Weaimed to systematically review studies evaluating the onset ofdifferent types of alopecia following COVID-19.Methods: The PubMed, Scopus, Web of Science, and Embasedatabases were searched with a specified string of relevantkeywords. After quality assessments, the data of eligible studieswere qualitatively and quantitatively synthesized.Results: Sixteen studies were included in our review, six ofwhich underwent meta-analysis for the differences in the risk ofalopecia between males and females. Though the disorder wasnot differentiated in all the cases, we found that COVID-19 wasassociated with several different types of alopecia, includingtelogen effluvium, alopecia areata, alopecia parvimaculata, andlichen planopilaris. Moreover, although statistically insignificant,the odds of developing alopecia favored the female population.Conclusion: Although many hypotheses have been suggested asto why an individual might be more predisposed to developingalopecia following COVID-19, the data obtained from the studiesyielded results that could not lead to definite conclusions. Therefore,we recommend that further studies be conducted to evaluatethe association between the two phenomena more confidently.
Behnam Avandi; Mehdi Ghahartars; Navid Moradi Kashkooli; Najmeh Ahramiyanpour; Mohammad Mahdi Parvizi
Abstract
Erythroderma or generalized scaling dermatitis is a condition marked by redness and scaling of more than 90% of the body surface. This study aimed to review the epidemiological and clinical features of erythroderma patients hospitalized in the Dermatology Ward of Shahid Faghihi Hospital, Shiraz, Iran. ...
Read More
Erythroderma or generalized scaling dermatitis is a condition marked by redness and scaling of more than 90% of the body surface. This study aimed to review the epidemiological and clinical features of erythroderma patients hospitalized in the Dermatology Ward of Shahid Faghihi Hospital, Shiraz, Iran. This retrospective cross-sectional was conducted from 2001 to 2017 using patient records. All patients with a diagnosis of erythroderma on record were included in the survey, and those whose data were missing or were not compatible with the clinical diagnosis were excluded. Data were analyzed with SPSS version 22 and Stata version 14.2. Overall, 217 erythroderma patients were admitted to this ward, including 119 (54.8%) men and 98 (45.2%) women. The mean age of the patients was 47.27 ± 19.68 years (range: 4-92 years). Moreover, the most frequent cause of erythroderma was drug reaction (67%); lamotrigine, with a frequency of 12 patients, was the most prevalent prescribed medication in patients with drug reaction-induced erythroderma. The mean duration of hospital stay was 6.64 ± 4.50 days; this parameter was directly associated with the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level. Pruritus (41.9%) and fever (15.2%) were the most frequent clinical manifestations among these patients. As erythroderma is a dermatologic condition that medications can induce, patients should be informed about the warning signals and course of the disease before certain medications are prescribed.
